Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07643766 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by Enveda Therapeutics.
- Not yet
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07643766 is a Phase 2 study that has not yet begun recruiting, run by Enveda Therapeutics. The registered enrollment target is 200 participants.
The verdict
NCT07643766, a Phase 2 study, has not yet begun recruiting, sponsored by Enveda Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive study treatment, and complete scheduled assessments of disease activity, symptoms, quality of life, safety, pharmacokinetics, and biomarker responses.
Interventions
- OTHER Placebo
- DRUG ENV-294
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07643766
The ClinicalTrials.gov registry entry for NCT07643766 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enveda Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07643766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07643766 about?
NCT07643766 is a clinical study titled "A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis". This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive st...
What is the current status of trial NCT07643766?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-06. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07643766?
The interventions under investigation include: Placebo (OTHER), ENV-294 (DRUG).
Who is sponsoring clinical trial NCT07643766?
This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.